No products approved for commercial sale
The company has no product revenue and must prove clinical and regulatory success before commercialization.
- Scope
- Entire business model
- Materiality
- high
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and related endocrine-driven cancers. Its pipeline centers on palazestrant and OP-3136, with development and future commercialization intended in the United States and other key markets, either independently or with partners.
9.95
9.95
| % | |
|---|---|
| Palazestrant | 55% Lead endocrine therapy candidate being developed for ER+ breast cancer in multiple settings. |
| OP-3136 | 25% KAT6 inhibitor program being evaluated for combination use in breast cancer. |
| Clinical development services | 15% Preclinical and clinical development activities supporting the pipeline. |
| Collaboration and partnering | 5% Research and development collaborations intended to expand development and commercialization reach. |
Olema does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites,...
- Clinical trial sites and investigatorsprimary
They run studies of palazestrant and OP-3136 and enable patient enrollment and data generation.
- Pharmaceutical collaboration partnersprimary
Partners such as Novartis and Pfizer collaborate on development and may support future commercialization.
- Contract manufacturers and service providersprimary
CMOs provide drug substance, drug product, labeling, and distribution for clinical supply.
- Future oncology prescribers and treatment centersemerging
If approved, oncologists and cancer centers would prescribe the therapies to patients with ER+ breast cancer.
Olema is headquartered in the United States and conducts its development activities through a global clinical and...
- •Headquartered in the United States
- •Clinical development and partnering extend beyond the U.S.
- •Commercialization is intended in key global markets
- •Third-party manufacturing may involve international supply chains
- •Foreign regulatory and IP regimes affect future expansion
Olema’s strategy is to advance palazestrant in multiple ER+ breast cancer indications and to develop OP-3136 as a...
01
Advance palazestrant across ER+ breast cancer settingsshort-term
The lead asset is the main value driver and the foundation of the pipeline.
02
Develop OP-3136 in combination regimensmedium-term
A second clinical program can broaden the pipeline and create combination opportunities.
03
Build partnering and commercialization optionalitymedium-term
External partners can add development speed, market access, and commercial infrastructure.
04
Secure scalable manufacturing readinessmedium-term
Commercial approval would require reliable API, fill-finish, and packaging capacity.
Olema faces the core risks of a clinical-stage biotech: no approved products, dependence on successful trials and...
Need for additional capital
Development-stage operations require ongoing funding for trials, manufacturing, and public-company costs.
- Scope
- Pipeline development and commercialization
- Materiality
- high
Clinical development and regulatory risk
Trial design, efficacy, safety, and approval decisions determine whether assets can advance.
- Scope
- Palazestrant and OP-3136
- Materiality
- high
Competitive intensity in oncology
Large pharma and biotech peers may develop similar or superior therapies faster.
- Scope
- ER+ breast cancer and endocrine-driven cancers
- Materiality
- high
Intellectual property protection
Value depends on protecting proprietary compounds and related uses across jurisdictions.
- Scope
- Palazestrant, OP-3136, future candidates
- Materiality
- high
Third-party manufacturing dependence
The company relies on CMOs for clinical and future commercial supply, creating execution and quality risk.
- Scope
- API, drug product, labeling, distribution
- Materiality
- medium
Accrued research and development expenses
Can shift operating expenses between quarters
Stock-based compensation
Affects reported losses and diluted share count
Collaboration and milestone accounting
Can create volatility in reported revenue or other income if applicable
Clinical and manufacturing commitments
Affects liabilities and cash requirement disclosures
Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances)
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
AMICUS THERAPEUTICS, INC.
Pharmaceutical Preparations
Biomea Fusion, Inc.
BMEA · Pharmaceutical Preparations
Oncopeptides
ONCO.ST · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
Omada Health, Inc.
OMDA · Services-Health Services
: 29.4.2026